Binimetinib CAS 606143-89-9

Product Description:

Product Name: binimetinib CAS NO: 606143-89-9

Synonyms:

hydroxyethoxy)amide;

MEK-162;

Chemical & Physical Properties:

Appearance: White to off white solid

Assay: ≥98.0%

Density: 1.67

Storage Condition: Dry, dark and at 0 - 4 ℃for short term (days to weeks) or -20 ℃for long term (months to years).

Solubility: Soluble in DMSO

Safety Information:

Caution Statements: P261-P305+P351+P338

Signal Word: Warning

Hazard Statements: H302-H315-H319-H335

Storage: Powder -20℃ 3 years 4℃2 years ;In solvent -80℃ 6 months -20℃ 1 month

Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma to treat various cancers.

It can be taken orally in tablet form.

In 2015 it was in phase 3 clinical trials for ovarian cancer, BRAF mutant melanoma, and NRAS Q61 mutant melanoma.

In Dec 2015 the company announced that the mutant-NRAS melanoma trial was successful. In the trial, those receiving binimetinib had a median progression-free survival of 2.8 months versus 1.5 months for those on the standard dacarbazine treatment. NDA submitted Jun 2016.

In April 2016 it was reported that the phase III trial for low-grade ovarian cancer was terminated due to lack of efficacy.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.